Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Elion

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
AIDS (London, England)|August 4, 2011
Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infectionRichard Elion, Calvin Cohen, Joseph Gathe, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 29, 2006
Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patientsEdwin DeJesus, Daniel Berger, Martin Markowitz, et al.
AIDS (London, England)|March 18, 2011
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infectionCalvin Cohen, Richard Elion, Peter Ruane, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 29, 2013
A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week resultsRichard Elion, Jean-Michel Molina, José Ramón Arribas López, et al.
AIDS (London, England)|August 24, 2017
Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomenMonica Gandhi, Pamela M Murnane, Peter Bacchetti, et al.
AIDS (London, England)|March 25, 2020
Quarterly screening optimizes detection of sexually transmitted infections when prescribing HIV preexposure prophylaxisEric C Tang, Eric Vittinghoff, Susan S Philip, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 17, 2019
Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence TestingMatthew A Spinelli, David V Glidden, Peter L Anderson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 10, 2017
Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration ProjectEric C Tang, Eric Vittinghoff, Peter L Anderson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 14, 2015
Sorting through the lost and found: are patient perceptions of engagement in care consistent with standard continuum of care measures?Amanda D Castel, Wenze Tang, James Peterson, et al.
JAMA Internal Medicine|June 20, 2017
Financial Incentives for Linkage to Care and Viral Suppression Among HIV-Positive Patients: A Randomized Clinical Trial (HPTN 065)Wafaa M El-Sadr, Deborah Donnell, Geetha Beauchamp, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
AIDS (London, England)|August 4, 2011
Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infectionRichard Elion, Calvin Cohen, Joseph Gathe, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 29, 2006
Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patientsEdwin DeJesus, Daniel Berger, Martin Markowitz, et al.
AIDS (London, England)|March 18, 2011
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infectionCalvin Cohen, Richard Elion, Peter Ruane, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 29, 2013
A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week resultsRichard Elion, Jean-Michel Molina, José Ramón Arribas López, et al.
AIDS (London, England)|August 24, 2017
Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomenMonica Gandhi, Pamela M Murnane, Peter Bacchetti, et al.
AIDS (London, England)|March 25, 2020
Quarterly screening optimizes detection of sexually transmitted infections when prescribing HIV preexposure prophylaxisEric C Tang, Eric Vittinghoff, Susan S Philip, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 17, 2019
Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence TestingMatthew A Spinelli, David V Glidden, Peter L Anderson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 10, 2017
Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration ProjectEric C Tang, Eric Vittinghoff, Peter L Anderson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 14, 2015
Sorting through the lost and found: are patient perceptions of engagement in care consistent with standard continuum of care measures?Amanda D Castel, Wenze Tang, James Peterson, et al.
JAMA Internal Medicine|June 20, 2017
Financial Incentives for Linkage to Care and Viral Suppression Among HIV-Positive Patients: A Randomized Clinical Trial (HPTN 065)Wafaa M El-Sadr, Deborah Donnell, Geetha Beauchamp, et al.
Pageof 3